New Oncology today announced that an abstract highlighting the company’s progress in clinical cancer genome diagnostics will be presented at the 16th World Conference on Lung Cancer taking place September 6 – 9, 2015, in Denver, USA.
Date & Time: Wednesday 9th September 2015, 9.45am – 10.45am and 3.45pm – 4.45am
Title: Discrepancies between ALK FISH and Capture Based NEOplus Diagnostics
Abstract: # 2748
Presenter: Dr. Rafał Dziadziuszko
“We analyzed primary tumor samples for our network of clinical partners using our NEO platform to detect therapeutically relevant gene fusions,” commented Dr. Lukas C. Heukamp, Medical Director of New Oncology. “In the cohort published today, our findings showed discrepant results in all cases when compared with fluorescent in situ hybridization (FISH), the current gold standard of gene fusion diagnostics. Clinical response data were available for all patients, and tumor sensitivity was always in line with the results obtained by NEO. With gene fusions becoming more and more important as cancer drug targets, the need for reliable results will drastically increase. With our NEO technology, we are perfectly adapted to analyze tumor samples that do not match the quality requirements for FISH analysis or for which only limited material is available.”